| Cancer Type | New Cases/Year | 5-Year Survival | Leading Cause |
|---|---|---|---|
| Lung | 2.4M | 23% | Smoking 🚬 |
| Breast | 2.3M | 90% | HR+/HER2- |
| Colorectal | 1.9M | 65% | Lynch syndrome |
Alarming Trend:
Under-50 cancer rates up 79% since 1990 (BMJ 2024)
| Method | Detection Limit | Key Use |
|---|---|---|
| Liquid Biopsy | 0.01% ctDNA | Early recurrence |
| PSMA-PET | 1mm prostate mets | 92% accuracy |
| AI Radiology | 94% tumor detection | Mammograms/CT |
FDA-Approved Novel Tests:
Galleri (50-cancer MCED test)
Signatera (ctDNA for 28
cancers)
| Type | Mechanism | Common Cancers | Key Drugs |
|---|---|---|---|
| Immunotherapy | PD-1/CTLA-4 blockade | Melanoma, NSCLC | Keytruda, Opdivo |
| Targeted Therapy | Gene mutation inhibition | BRCA+, EGFR+ | Lynparza, Tagrisso |
| CAR-T | Engineered T-cells | Lymphoma, Myeloma | Yescarta, Abecma |
2024 Breakthrough:
TIL therapy shows 50% response in solid tumors (Phase III)
| Complication | Intervention | Onset |
|---|---|---|
| Neutropenia | Neulasta | Chemo day 2 |
| Neuropathy | Duloxetine | Cumulative |
| CRS* | Tocilizumab | CAR-T day 3 |
*Cytokine Release Syndrome
2024 Essentials:
HRD testing now standard for ovarian cancer
TMB-H predicts immunotherapy response
NCI Match Trial: 143 treatment arms
ESMO Scale: Benefit magnitude (1-5)
AI Tools: Trialjectory (83% match accuracy)
| Need | Intervention | Evidence |
|---|---|---|
| Fatigue | CBT + Exercise | 52% improvement |
| Chemo Brain | Memantine | 30% cognitive gain |
| Sexual Health | Testosterone/Vaginal estrogen | RCT-proven |
Oncofertility Update:
Ovarian suppression during chemo preserves fertility in 78%
| Cancer | Test | Frequency | Start Age |
|---|---|---|---|
| Breast | MRI + Mammo | Annual | 40 (High-risk 30) |
| Colon | FIT-DNA | 3 years | 45 |
| Lung | LDCT | Yearly | 50 (20 pack-year) |
Controversy:
PSA screening now recommended for Black men at 40
| Type | Survival | Novel Therapy |
|---|---|---|
| ALL | 90% | Blinatumomab |
| Neuroblastoma | 75% | GD2 vaccine |
| DIPG* | 10% | ONC201 trials |
*Diffuse Intrinsic Pontine Glioma
2024 Hope:
CAR-T for solid tumors (NCT05607567)
| Region | Breast Cancer 5YS | Barriers |
|---|---|---|
| USA | 90% | Cost (Avg $150k) |
| India | 66% | Late diagnosis |
| Nigeria | 40% | HER2 testing access |
WHO 2030 Goal:
60% global HPV vaccination (Prevents 6 cancers)
NCI Cancer.gov (Clinical trial finder)
CancerCare (Free counseling)
ASCO eLearning (CME credits)
NCCN Guidelines (Free app)